Ponatinib After Failure of Second-Generation TKIs in Resistant Chronic-Phase CML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
American Journal of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia
Am. J. Hematol 2022 Aug 12;[EPub Ahead of Print], HM Kantarjian, E Jabbour, M Deininger, E Abruzzese, J Apperley, J Cortes, C Chuah, DJ DeAngelo, J DiPersio, A Hochhaus, J Lipton, FE Nicolini, J Pinilla-Ibarz, D Rea, G Rosti, P Rousselot, NP Shah, M Talpaz, S Srivastava, X Ren, M MauroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.